Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical,
device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In
order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount
Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Dorfman did not report having any of the following types of financial relationships with industry during 2016 and/or 2017:
consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees,
equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company.
Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our
Patients may wish to ask their physician about the activities they perform for companies.